Understanding the barriers to, and facilitators of, ovarian toxicity assessment in breast cancer clinical trials

Wanyuan Cui\textsuperscript{a,b}, Kelly-Anne Phillips\textsuperscript{a,b,c,d}, Prudence A. Francis\textsuperscript{a,b,c}, Richard A. Anderson\textsuperscript{e}, Ann H. Partridge\textsuperscript{f}, Sherene Loi\textsuperscript{a,b,g}, Sibylle Loibl\textsuperscript{h}, Louise Keogh\textsuperscript{j,1}

\textsuperscript{a} The Sir Peter MacCallum Department of Oncology, The University of Melbourne, 305 Grattan St, Melbourne, 3000, VIC, Australia
\textsuperscript{b} Department of Medical Oncology, Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne, VIC, 3000, Australia
\textsuperscript{c} Breast Cancer Trials Australia New Zealand (BCT-ANZ), Level 4, 175 Scott St, Newcastle, 2300, NSW, Australia
\textsuperscript{d} Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia
\textsuperscript{e} MRC Centre for Reproductive Health, University of Edinburgh, 47 Little France Crescent, Edinburgh, EH16 4TJ, UK
\textsuperscript{f} Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA
\textsuperscript{g} Division of Research, Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne, VIC, 3000, Australia
\textsuperscript{h} German Breast Group, Martin Behaim Strasse 12, 63263, Neu-Isenburg, Germany
\textsuperscript{i} Centre for Haematology and Oncology, Bethanien, Im Prüfling 17, 60389, Frankfurt, Germany
\textsuperscript{j} Centre for Health Equity, The University of Melbourne, Parkville, VIC, 3010, Australia

ARTICLE INFO

Keywords:
Fertility
Ovarian insufficiency
Menopause
Breast cancer
Clinical trials
Qualitative research

ABSTRACT

Background: Detailed toxicity data are routinely collected in breast cancer (BC) clinical trials. However, ovarian toxicity is infrequently assessed, despite the adverse impacts on fertility and long-term health from treatment-induced ovarian insufficiency.

Objectives: To determine the barriers to and facilitators of ovarian toxicity assessment in BC trials of anti-cancer drugs.

Methods: Semi-structured interviews were conducted with purposively selected stakeholders from multiple countries involved in BC clinical trials (clinicians, consumers, pharmaceutical company representatives, members of drug-regulatory agencies). Participants were asked to describe the perceived benefits and barriers to evaluating ovarian toxicity. Interviews were transcribed verbatim, coded in NVivo software and analysed using inductive thematic analysis.

Results: Saturation of the main themes was reached and the final sample size included 25 participants from 14 countries (9 clinicians, 7 consumers, 5 members of regulatory agencies, 4 pharmaceutical company representatives); half were female. The main reported barrier to ovarian toxicity assessment was that the issue was rarely considered. Reasons included that these data are less important than survival data and are not required for regulatory approval. Overall, most participants believed evaluating the impact of BC treatments on ovarian function is valuable. Suggested strategies to increase ovarian toxicity assessment were to include it in clinical trial design guidelines and stakeholder advocacy.

Conclusion: Lack of consideration about measuring ovarian toxicity in BC clinical trials that include premenopausal women suggest that guidelines and stronger advocacy from stakeholders, including regulators, would facilitate its more frequent inclusion in future trials, allowing women to make better informed treatment decisions.

1. Introduction

Ovarian toxicity is a potentially irreversible adverse effect of anti-cancer treatment for premenopausal women with breast cancer (BC). It can result in infertility, and can have profound impacts on longer-term bone density, cardiovascular health and cognitive function [1–3]. As the incidence of BC in premenopausal women increases [4], and survival rates improve [5], minimising long-term treatment-related adverse effects in young women is paramount.
The impact of cancer treatments on fertility and ovarian function is a significant concern for premenopausal women with BC [6,7] and is an important consideration when making treatment decisions [7]. Inter-professional collaboration is crucial for addressing the potential impact of treatment on fertility and ovarian function [8–14]. However, little is known about the ovarian effects of newer classes of anti-cancer therapies. A recent systematic evaluation demonstrated that ovarian toxicity is infrequently assessed in phase 3 (neo)adjuvant early BC clinical trials which enrolled premenopausal women [15], so the relevant information needed for informed decision-making for premenopausal women is usually not available when they are first used in practice.

Many stakeholders are involved in the design of clinical trials, including clinicians, drug-regulatory agencies, patient advocates (consumers) and pharmaceutical companies [16,17]. Phase 3 BC trials are often global multicentre studies, and stakeholders from different countries are involved in their design. It is not clear why ovarian toxicity endpoints are rarely assessed in trials enrolling premenopausal women. Existing qualitative research primarily focuses on the barriers to ovarian preservation [18]. Qualitative research has been important for the incorporation of patient reported outcomes in clinical trials [19], and for examining trial design uncertainties [20]. Therefore, this international qualitative study was designed to determine the barriers and facilitators to ovarian toxicity assessment in BC clinical trials from the perspective of key decision-makers.

2. Methods

2.1. Design

Through semi-structured interviews with key decision-makers in BC clinical trials, this qualitative study explored the barriers to and facilitators of ovarian toxicity assessment in curative-intent pharmacological BC trials which enrol premenopausal women. Approval was obtained from the Peter MacCallum Cancer Centre Human Research and Ethics Committee (LNR/61921/PMCC).

2.2. Participants

Key decision-makers regarding clinical endpoints in BC trials are trial investigators (clinicians), consumers, pharmaceutical companies which produce BC anti-neoplastic agents [21], and drug-regulatory agencies. We purposively sampled for individuals from each of these groups, who had been personally involved in the design and conduct of BC trials or in drug regulation for BC anti-neoplastic agents in the last 10 years, and who were able to speak English and participate in an interview. We sought to include eligible participants from a range of countries.

Clinicians were eligible for the study if they were lead authors (first, second or last) of published phase 3 (neo)adjuvant BC trial manuscripts, or listed as the responsible party on clinicaltrials.gov or EudraCT databases, or were scientific advisory committee members of collaborative trial groups. Consumers were eligible if they were consumer advisors for BC collaborative trial groups. Pharmaceutical company representatives (pharmaceutical company employees involved in trial design: medical advisors, chief scientific officers, chief research and development managers) and advisory committee members of drug-regulatory agencies (Food and Drug Administration (FDA), European Medicines Agency (EMA) or Pharmaceutical Benefits Advisory Committee) were eligible for inclusion and were identified through public internet search. To identify pharmaceutical company representatives, the website and LinkedIn page of each pharmaceutical company was searched. To identify regulatory agency members, the regulatory agency website and drug advisory committee meeting materials were searched. In order to extend the sample and identify other important stakeholders, snowball sampling was also conducted by asking participants to forward the email invitation to colleagues they believed would meet the inclusion criteria. Eligibility was checked by the researchers prior to interview for participants recruited through this process.

Eligible participants were sent an email or social-media invitation and a participant information sheet. If no response was received a reminder letter and a final email or social-media contact were sent. Consent was implied if the participant responded and provided contact details and a time for the interview.

2.3. Data collection and analysis

The study investigators included BC clinical trialists (clinicians), a reproductive specialist and a health sociologist. An interview guide was developed exploring the following questions: i) who contributes to trial endpoint selection, ii) what factors are considered during decision-making, iii) are ovarian toxicity endpoints included, iv) barriers to and/or benefits of ovarian toxicity assessment in BC trials, and v) strategies to improve ovarian toxicity evaluation. Only data related to themes iii), iv) and v) are reported in this paper, themes i) and ii) will be reported elsewhere. Interview questions were refined following piloting with colleagues initially, then one BC clinician who met the eligibility criteria; the pilot interview with the clinician who met the eligibility criteria was included in the overall analysis.

Semi-structured interviews were conducted by phone or video-conference by one author (WC, medical oncologist). The interviewer obtained verbal consent before each interview. Participants were initially asked closed-ended questions to collect demographic data. The themes covered in the interview were: the participant views on whether ovarian function endpoints were considered during trial design, whether these endpoints were important to include (why/why not), the barriers to their inclusion and the facilitators/strategies to improve their inclusion. All interviews were audio-recorded and professionally transcribed verbatim. Transcripts were de-identified after the transcription process. Transcripts were not returned to participants for comment after the interview. Grammatical changes were made to quotes for readability.

Inductive thematic analysis was performed by reading the transcripts in order to develop a coding framework, framework analysis was then undertaken to structure themes and to further analyse the emerging themes in light of the research question facilitated using NVivo software [22]. After five interviews, a summary of the emerging themes with supporting quotes was collated by one author (WC). Emerging themes were reviewed by co-authors LK (health sociologist) and KAP (medical oncologist) for feedback regarding the key themes and any refinements required for the interviews. After 15 interviews, a coding framework capturing the full range of comments was developed by WC and reviewed by co-authors LK and KAP. After interview 15, new interviews were reviewed in light of the coding framework to determine whether saturation of the main themes had been achieved. Two authors (WC and LK) independently coded several interviews and the coding framework was further refined. WC coded the remaining transcripts according to the coding framework. The final coding framework was discussed with
all study investigators (listed authors).

3. Results

3.1. Participants

Between June 2020 and April 2021, 260 stakeholders were invited to participate. 18 participants responded to the initial email invitation. Reminders were purposively sent to stakeholders who were from North America and Asian regions, members of drug-regulatory agencies and pharmaceutical company representatives, to broaden the range of participant demographics. Saturation was reached when no new themes were identified after interview 21. Another four interviews were conducted and no new themes were identified, therefore no further interviews were conducted after interview 25. The final sample included: 9 clinicians, 7 consumers, 5 members of drug-regulatory agencies, 4 pharmaceutical company representatives; half were female (Table 1). Interviews ranged between 24 and 46 min in duration.

### Table 1

| Characteristics of study participants. | Participants | N = 25 |
|---------------------------------------|--------------|--------|
| **Age**                               |              |        |
| Median (years)                         | 50 years     |        |
| 30–39 years                           | 5 (20%)      |        |
| 40–49 years                           | 7 (28%)      |        |
| 50–59 years                           | 10 (40%)     |        |
| 60–69 years                           | 3 (12%)      |        |
| **Gender**                            |              |        |
| Male                                  | 13 (52%)     |        |
| Female                                | 12 (48%)     |        |
| **Region**                            |              |        |
| North America                         | 5 (20%)      |        |
| Europe                                | 13 (52%)     |        |
| Australia                             | 6 (24%)      |        |
| Asia                                  | 1 (4%)       |        |
| **Stakeholder type**                  |              |        |
| Clinician                             | 9 (36%)      |        |
| Consumer                              | 7 (28%)      |        |
| Regulatory agency member              | 5 (20%)      |        |
| Pharmaceutical company representative | 4 (16%)      |        |
| **Years of experience**               |              |        |
| Median (years)                        | 16 years     |        |
| 1–5 years                             | 3 (12%)      |        |
| 6–10 years                            | 8 (32%)      |        |
| 11–20 years                           | 5 (20%)      |        |
| 21–30 years                           | 8 (32%)      |        |
| >30 years                             | 1 (4%)       |        |
| **Member of a cooperative trials group scientific advisory committee** | | |
| Yes                                   | 19 (76%)     |        |
| No                                    | 6 (24%)      |        |
| **Previously/currently a member of a pharmaceutical company advisory board** | | |
| Yes                                   | 16 (64%)     |        |
| No                                    | 9 (36%)      |        |
| **Previously led a clinical trial as a lead investigator** | | |
| Yes                                   | 10 (40%)     |        |
| No                                    | 8 (32%)      |        |
| NA (consumer)                         | 7 (28%)      |        |
| **Previously received training in clinical trial design** | | |
| Yes                                   | 12 (48%)     |        |
| No                                    | 6 (24%)      |        |
| NA (consumer)                         | 7 (30%)      |        |

Abbreviation: NA - not applicable.

* Three members of drug-regulatory agencies answered yes to this question.

** This includes clinicians and consumers who have acted as advisors for pharmaceutical companies as part of an advisory board, as well as current employees of pharmaceutical companies.

3.2. Why are ovarian toxicity data infrequently included in breast cancer clinical trials?

Almost all participants reported that ovarian toxicity is rarely assessed in BC clinical trials. Four main barriers were reported. The main reported barrier was that this issue was rarely prioritised (barrier 1). Other important barriers included limited trial resources (barrier 2), lack of knowledge regarding how to assess treatment-related ovarian toxicity (barrier 3) and settings where these data were considered less relevant (barrier 4). Table 2 details the proportion of participants who reported each barrier, Appendix Table 1 describes the quotes to support each of these barriers.

3.2.1. Not prioritised

Almost all participants reported that ovarian toxicity was not prioritised and infrequently discussed during trial design. Ovarian toxicity was often deemed not the primary question of clinical trials and more than half of the participants reported that ovarian toxicity was considered less important than survival endpoints. Indeed, one consumer stated “There’s still that pervasive idea that if we keep you alive the rest doesn’t matter.” Furthermore, collection of ovarian toxicity data is not required for regulatory approval of cancer drugs; this was a key barrier identified by one pharmaceutical company advisor and almost all members of drug-regulatory agencies.

3.2.2. Considered too resource intensive

Many participants reported the pressure on trial resources required to assess ovarian toxicity, such as the cost and the additional burden on investigators and patients was perceived as prohibitive. Concerns regarding the duration of follow-up required to capture fertility events and loss of ovarian function, and the difficulty in collecting good quality data during the follow-up period were also distinctive barriers.

3.2.3. Lack of knowledge

Another barrier, particularly reported by clinicians, was the need for guidance regarding which ovarian markers are most useful to assess. Participants also reported that stakeholders designing clinical trials may not know the potential ovarian side-effects of the anti-cancer drugs they are studying.

3.2.4. Assessing ovarian toxicity may be less relevant in certain settings

Assessing ovarian toxicity was considered as less relevant in certain settings, such as trials where low numbers of premenopausal women are included. One quarter of participants reported that ovarian toxicity assessment may be difficult in trials where patients also receive concurrent gonadotoxic chemotherapy. Additionally, trials investigating hormone-receptor positive BC, where drugs are specifically administered to induce ovarian suppression [23], might make additional assessment of ovarian toxicity more challenging.

3.3. What are the perceived benefits of including ovarian toxicity endpoints?

Despite the perceived barriers, overall, participants felt that evaluating the impact of BC treatments on ovarian function was valuable. Indeed, one clinician stated that lack of ovarian toxicity assessment was “a failure of the entire research world”.

The two main benefits of including ovarian endpoints are these data are important to i) patients and ii) clinicians. Supporting quotes are provided in Appendix Table 2.

3.3.1. Data are important to patients

The importance of such data to patients was recognised by almost all clinicians and consumers, and half of the pharmaceutical company representatives and members of regulatory agencies. The impact of gonadotoxicity on a woman’s quality of life (QOL), and the importance
of these data in informing cancer-treatment and family-planning decisions were leading reasons why these data should be assessed. Furthermore, information regarding the potentially irreversible impact of cancer treatments on ovarian function was seen as important to avoid unknown long-term side-effects.

3.3.2. Data are important to clinicians

Participants reported that ovarian toxicity assessment may help clinicians better understand the investigational agent and improve counselling their patient regarding treatment options. Indeed, one pharmaceutical company representative reported that “If you had two molecules that behaved in the same way, but one of them was able to result in better preservation of ovarian function than the other, then that would be a benefit that you could then make a claim in.” Moreover, there is increasing interest in the impact of ovarian suppression on disease outcomes, and these data may enrich interpretation of trial results. These data were also identified as best collected prospectively, as gonadotoxicity can be difficult to assess retrospectively.

3.4. What are strategies that might help to increase the inclusion of ovarian toxicity endpoints?

Participants identified two main strategies: i) increased awareness and ii) increased stakeholder advocacy for these data to be assessed as important facilitators for the collection of these data in future trials (see Table 3 for further detail and Appendix Table 3 for supporting quotes).

3.4.1. Increased stakeholder awareness

Primarily, increased awareness through trial design guidelines was a central strategy reported by half of participants. One member of a drug-regulatory agency stated “Whenever we come up with a conundrum, that’s when we look at [National Comprehensive Cancer Network] guidelines or St Gallen’s […] Having consensus with guidelines would be a great start.”

Other strategies to increase ovarian toxicity assessment included improving familiarity with ovarian function markers among trial design decision-makers and increased discussion regarding gonadotoxicity within the scientific community.

3.4.2. Increased stakeholder advocacy

A stronger consumer voice and clinician promotion were regarded as especially important by most participants. In addition, some participants felt that drug-regulatory agencies could also play an influential role in guiding sponsors and/or clinical trialists regarding the importance of ovarian toxicity assessment in trials. Other stakeholders identified as key to advocate for these data to be assessed included reproductive specialists and cooperative trials groups. Only two participants reported

| Reason                                                                 | Number of participants who reported each reason |
|------------------------------------------------------------------------|-----------------------------------------------|
| Why are ovarian toxicity data infrequently included in breast cancer clinical trials? |
| Overall (n = 25) | Clinician (n = 9) | Consumer (n = 7) | Pharmaceutical company representative (n = 4) | Member of drug-regulatory agency (n = 5) |
| 1 Not prioritised | Not discussed or thought about | 23 | 9 | 7 | 3 | 4 |
|                     | Not the primary question or most important endpoint(s) studied by clinical trial | 16 | 7 | 4 | 4 | 1 |
|                     | Not required for regulatory approval | 5 | 0 | 0 | 1 | 4 |
|                     | More appropriate for a follow up/registry study | 3 | 1 | 1 | 0 | 1 |
| 2 Considered too resource intensive | A burden on investigators and patients | 9 | 4 | 1 | 2 | 2 |
|                     | Time to obtaining results too long | 7 | 1 | 3 | 1 | 2 |
|                     | Assessment not considered feasible | 5 | 3 | 0 | 2 | 0 |
|                     | Too costly | 5 | 2 | 2 | 1 | 0 |
|                     | Difficult to collect good quality data | 2 | 0 | 0 | 2 | 0 |
| 3 Lack of knowledge | Need for guidance regarding which markers to assess | 6 | 5 | 0 | 0 | 1 |
|                     | Lack of existing knowledge or preclinical data regarding ovarian toxicity side effects | 4 | 3 | 0 | 1 | 0 |
| 4 Assessing ovarian toxicity may be less relevant in certain settings | Low numbers of premenopausal women enrolled | 7 | 3 | 3 | 0 | 1 |
|                     | Trials mandate contraception use | 7 | 2 | 2 | 0 | 3 |
|                     | Concurrent use of gonadotoxic chemotherapy | 6 | 3 | 2 | 1 | 0 |
|                     | Want to suppress ovarian function in some breast cancer phenotypes | 6 | 1 | 2 | 2 | 1 |

What are the perceived benefits of including ovarian function endpoints?

| Reason | Number of participants who reported each reason |
|--------|-----------------------------------------------|
| Overall (n = 25) | Clinician (n = 9) | Consumer (n = 7) | Pharmaceutical company representative (n = 4) | Member of drug-regulatory agency (n = 5) |
| 1 Data are important to patients | Infertility and early menopause are relevant and important to patients | 18 | 7 | 7 | 2 | 2 |
|                     | Improved ability to make informed cancer treatment and family planning decisions | 11 | 3 | 6 | 1 | 1 |
|                     | Preservation of ovarian function is important for quality of life | 10 | 4 | 5 | 0 | 1 |
| 2 Data are important to clinicians | To avoid potential harm to patients | 4 | 2 | 2 | 0 | 0 |
|                     | Improved understanding of the investigational agent | 9 | 3 | 2 | 1 | 2 |
|                     | Improved understanding of the impact of ovarian function on disease outcomes | 7 | 4 | 1 | 1 | 1 |
|                     | Improved ability to counsel patients | 7 | 5 | 1 | 1 | 0 |
|                     | Prospective information is more valuable | 3 | 2 | 1 | 0 | 0 |
increased interest from pharmaceutical companies as a strategy to increase the inclusion of ovarian toxicity assessment in BC trials.

4. Discussion

To our knowledge, this is the first study exploring the barriers and potential facilitators to assessment of ovarian toxicity in BC clinical trials. Despite the importance of avoidance of unnecessary treatment-induced menopause, we found that ovarian toxicity assessment was not prioritised and rarely even considered during trial design. Overall, key stakeholders of BC trials felt that assessing ovarian toxicity was important, and that these data were necessary to inform treatment decisions. We have identified a disconnect between what stakeholders desire to know, and what is currently assessed in BC trials.

Many participants in this study recognised that preservation of ovarian function was fundamental to a woman’s QOL. Yet, the majority felt these data were currently under-prioritised during trial design. QOL is now considered an endpoint for clinical benefit by the FDA and leading oncology organisations [24,25], which has led to increased incorporation of QOL assessment in cancer clinical trials [26,27].

Similar to the experience of incorporating QOL assessment, increased awareness regarding the importance of ovarian toxicity data among trial design decision-makers was highlighted as a core strategy to increase assessment of ovarian toxicity.

We found that different stakeholders prioritised ovarian toxicity assessment differently. Although almost all clinicians and consumers reported that ovarian toxicity data were important, only half of the pharmaceutical company representatives and members of drug-regulatory agencies shared this view. Regulatory requirements may be an important strategy to ensure incorporation of ovarian toxicity assessment given their influence on the pharmaceutical industry. Further expansion of the FDA guidance for industry documents [28] and similar guidance from the EMA may lead to improved prioritisation of ovarian toxicity in trials enrolling premenopausal women.

A need for increased guidance regarding how to assess gonadotoxicity was considered another barrier to routine inclusion of these data. Indeed, in BC trials which do assess ovarian toxicity, including gonadotrophin-releasing-hormone analogue (GnRHa) trials where treatment-induced ovarian insufficiency was the primary endpoint, the ovarian measures used are variable, and arguably inadequate [29]. Furthermore, menstruation is often used to assess ovarian function [30]. Yet, reduced ovarian function can occur in women who are still menstruating and anti-cancer drugs may deplete the ovarian reserve without stopping menses [31].

Some participants considered that the gonadotoxic effects of the non-investigational chemotherapy clouds the interpretation of the ovarian toxic effects of novel cancer treatments. However, many novel agents may be given in a prolonged maintenance phase after chemotherapy has finished [32–35], at a time when “ovarian protection” measures may be discontinued. Therefore, ovarian toxicity assessment of these novel agents is still pertinent regardless of whether they are initially combined with chemotherapy or not. On the contrary, participants felt that assessing ovarian function may help assess the impact of these changes on cancer outcomes and enhance interpretation of trial results. This is particularly relevant for hormone-receptor positive BC where ovarian suppression has been shown to impact cancer outcomes [23]. Oestrogen also modifies the function of immune-cell populations [36]. This is relevant in triple-negative BC, where immunotherapy is now licenced [33,37]; trials assessing immunotherapy for other BC subtypes are also underway.

Another perceived barrier to ovarian toxicity assessment is the desire not to add excessive burden on the finite trial resources. There is a notable paradox between the detailed requirements in trial protocols to mandate often multiple contraceptive methods and pregnancy tests in women of potential child-bearing capacity throughout trial drug administration, but lack of attention to ovarian toxicity during and after treatment. Improved agreement regarding the most informative markers of ovarian toxicity could improve interpretation of such data and also minimise collection of unnecessary data and reduce resource intensity.

The duration of follow-up required was another perceived barrier. However, longer-term monitoring for late cancer-treatment toxicities is increasingly practiced [38,39]. Prospective cardiac surveillance is now often incorporated into trial protocols of cardiotoxic BC treatments, sometimes up to 10 years after treatment completion [40], demonstrating the feasibility to understand the existence of late treatment toxicities.

Guidelines are an important tool to guide best clinical practice, and were a key strategy suggested by participants to improve implementation of ovarian toxicity assessment. Current tools used for trial endpoint decision-making [25,41,42] do not address ovarian toxicity assessment. As reported by many participants in this study, development of clinical trial design guidelines which make recommendations regarding which ovarian measures to collect and when, may overcome many of the barriers we identified [43].

There were several limitations to this study. All interviews were conducted by phone or video-conference to allow international stakeholders to participate. Only one participant from Asia was included, and our findings may not be generalisable for this region; a barrier to
participation may be that the interviews were conducted in English and this study was conducted during the COVID-19 pandemic. Half of stakeholders included were involved in industry-sponsored trials, given these are generally more prevalent; but three-quarters were also involved in cooperative group coordinated trials and therefore our findings are relevant to both trial types. Although we sampled stakeholders from different backgrounds, there may be participation bias as participants may be more likely to have known more about or been more interested in the question of measuring ovarian toxicity than non-participants. Moreover, other stakeholders involved in trial design such as statisticians were not interviewed. Lastly, this study was exploratory in nature and represents the opinions of participants. Therefore, the data presented in this study is subjective, a caveat of our study design.

5. Conclusion

Despite the potential profound impact of treatment-related ovarian toxicity for premenopausal women, this qualitative study found that ovarian toxicity assessment in BC trials is currently not prioritised. Yet, stakeholders, particularly consumers, believe that assessing ovarian toxicity is important and these data are vital to inform treatment decisions. Stronger advocacy is needed to change practice. Clinical trial design guidelines may break down many of the existing barriers to ovarian toxicity assessment, raise awareness of this important knowledge gap and provide guidance on how to collect informative data while minimising the burden on trial resources. Inclusion of ovarian toxicity assessment in future trials will provide invaluable information regarding a potentially serious adverse effect of cancer treatment, to ultimately empower women to make fully-informed treatment decisions that will impact their family-planning choices and long-term health.

Funding

This work was supported by a grant from Breast Cancer Trials Australia New Zealand (BCT-ANZ). The funder was not involved in the study design, data collection, interpretation or reporting. KAP is an NHMRC Leadership Fellow. WC was supported by an Australian Government Research Scholarship for submitted work.

Declaration of competing interest

W Cui: Dr Cui reports honoraria from AstraZeneca, Pfizer, Janssen and Merck.
KA Phillips: Professor Phillips reports two unpaid Advisory Boards for AstraZeneca in 2021. Breast Cancer trials Scientific Advisory Committee member. Breast Cancer Network Australia Strategic Advisory Committee member.
PA Francis: Professor Francis is the Breast Cancer Trials Australia & New Zealand Chair Scientific Advisory Committee member. She reports travel overseas: Novartis, Ipsen.
RA Anderson: Professor Anderson reports personal fees and non-financial support from Roche Diagnostics, outside the submitted work.
AH Partridge: Professor Partridge reports travel to lecture overseas: Novartis, Pfizer.

S Loi: Professor Loi receives research funding to her institution from Novartis, Bristol Meyers Squibb, Merck, Puma Biotechnology, Eli Lilly, Nektar Therapeutics AstraZeneca, Roche-Genentech and Seattle Genetics. She has acted as consultant (not compensated) to Seattle Genetics, Novartis, Bristol Meyers Squibb, Merck, AstraZeneca and Roche-Genentech. She has acted as consultant (paid to her institution) to Aduro Biotech, Novartis, GlaxoSmithKline, Roche-Genentech, AstraZeneca, Silverback Therapeutics, G1 Therapeutics, PUMA Biotechnologies, Seattle Genetics and Bristol Meyers Squibb. Professor Loi is a Scientific Advisory Board Member of Akamara Therapeutics. She is supported by the National Breast Cancer Foundation of Australia Endowed Chair and the Breast Cancer Research Foundation, New York.

Acknowledgements

The authors wish to acknowledge the Breast Cancer Trials Australia New Zealand (BCT-ANZ) Consumer Advisory Panel for their assistance in the grant application for this study, and all the clinicians, consumers, pharmaceutical company representatives and members of regulatory agencies for their participation in this study.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.breast.2022.05.002.

References

[1] Mar Fan HG, Houde-Tchen N, Chemerynsky I, et al. Menopausal symptoms in women undergoing chemotherapy-induced and natural menopause: a prospective controlled study. Ann Oncol 2010;21(5):586-7.
[2] Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 2001;19(14):3306-11.
[3] European Society for Human Reproduction Embryology Guideline Group on POI, Webber L, Davies M, Anderson R, et al. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum Reprod 2020;36(5):296-37.
[4] Thomas A, Rhoads A, Pinkerton E, et al. Incidence and survival among young women with stage I-iii breast cancer: SEER 2000-2015. JNCI Cancer Spectr 2019;3(3):pkz040.
[5] National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Female Breast Cancer 2021. https://seer.cancer.gov/statfacts/html/breast.html. Access date 25 July 2021.
[6] Christian N, Gemignani ML. Issues with fertility in young women with breast cancer. Curr Oncol Rep 2019;21(7):58.
[7] Ruddy KJ, Gelber SI, Tamimi RM, et al. Prospective study of fertility concerns and preservation strategies in young women with breast cancer. J Clin Oncol 2014;32(11):1515-6.
[8] Lambertini M, Peccatori FA, Demeester E, et al. Fertility preservation and postponed treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 2020;31(12):1664-78.
[9] van Dorp W, Mulder RL, Kremer LC, et al. Recommendations for premature ovarian insufficiency surveillance: female survivors of childhood, adolescent, and young adult cancer: a report from the international late effects of childhood cancer guideline harmonization group in collaboration with the PanCareSurF consortium. J Clin Oncol 2016;34(28):3440–50.
[10] Paluch-Shimon S, Cardoso F, Partridge AH, et al. ESO-ESMO 4th international consensus guidelines for breast cancer in young women (BCY4). Ann Oncol 2020;31(6):674-96.
[11] Coccia PF, Pappo AS, Beaupin L, et al. Adolescent and young adult oncology, version 2.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 2018;16(1):66-97.
[12] Jackisch C, Harbeck N, Huso J, et al. 14th St. Gallen international breast cancer conference 2015: evidence, controversies, consensus - primary therapy of early breast cancer: opinions expressed by German experts. Breast Care 2015;10(3):211-9.
[13] Oktay K, Harvey BE, Partridge AH, et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 2018;36(19):1994-2001.
[14] Anderson RA, Amant F, Braat D, et al. ESHRE guideline: female fertility preservation. Hum Reprod Open 2020;2020(4). hooa052.
[15] Cui W, Francis PA, Loi S, et al. Assessment of ovarian function in phase 3 (Neo) adjuvant breast cancer clinical trials: a systematic evaluation. J Natl Cancer Inst 2021;113(12):1790–8.

[16] Blagden SP, Billingham L, Brown LC, et al. Effective delivery of Complex Innovative Design (CID) cancer trials:A consensus statement. Br J Cancer 2020;122 (4):473–82.

[17] Marsden J, Bradburn J, Consumers’ Advisory Group for Clinical Trials. Patient and clinician collaboration in the design of a national randomized breast cancer trial. Health Expect 2004;7(1):6–17.

[18] Panagiotopoulou N, Ghuman N, Sandher R, et al. Barriers and facilitators towards fertility preservation care for patients: a meta-synthesis. Eur J Cancer Care 2018;27(1). https://doi.org/10.1111/ecc.12428.

[19] Lasch KE, Marquis P, Vigneux M, et al. PRO development: rigorous qualitative research as the crucial foundation. Qual Life Res 2010;19(8):1087–96.

[20] O’Catthain A, Hoddinott P, Levin S, et al. Maximising the impact of qualitative research in feasibility studies for randomised controlled trials: guidance for researchers. Pilot Feasibility Stud 2015;1:32.

[21] National Cancer Institute. Drugs Approved for Breast Cancer 2019. https://www.cancer.gov/about-cancer/treatment/drugs/breast. Access date: 3 June 2020.

[22] Green J, Thorogood N. Qualitative methods for health research. Los Angeles, California: Sage; 2014.

[23] Francis PA, Pagani O, Fleming GF, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med 2018;379(2):122–37.

[24] Seidman AD, Bordeleau L, Fehrenbacher L, et al. National cancer institute breast cancer steering committee working group report on meaningful and appropriate end points for clinical trials in metastatic breast cancer. J Clin Oncol 2018: JCO1800242.

[25] Chemy NI, Dafni U, Bogaerts J, et al. ESMO-magnitude of clinical benefit scale version 1.1. Ann Oncol 2017;28(10):2340–66.

[26] U.S. Food and Drug Administration. Clinical trial endpoints for the approval of cancer drugs and biologics. 2018. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-trial-endpoints-approval-cancer-drugs-and-biologics. [Accessed 31 January 2020].

[27] Verma S, McLeod D, Bistrit G, et al. In the end what matters most? A review of clinical endpoints in advanced breast cancer. Oncol 2011;16(1):25–35.

[28] U.S. Food and Drug Administration. Premenopausal women with breast cancer: developing drugs for treatment. Guidance for Industry, 2021. https://www.fda.gov/. [Accessed 1 July 2021].

[29] Lambertini M, Moore HCF, Leonard RCF, et al. Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: a systematic review and meta-analysis of individual patient-level data. J Clin Oncol 2018;36(19):1981–90.

[30] Silva C, Caramelo O, Almeida-Santos T, et al. Factors associated with ovarian function recovery after chemotherapy for breast cancer: a systematic review and meta-analysis. Hum Reprod 2016;31(12):2737–49.

[31] Oktay K, Öktean O, Reh A, et al. Measuring the impact of chemotherapy on fertility in women with breast cancer. J Clin Oncol 2006;24(24):4046–4.

[32] Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med 2021;384(25):2594–405.

[33] Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med 2020;382(9):810–21.

[34] Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR⁺, HER2-, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol 2020;38(34):3987–98.

[35] Mayer EL, Duerck AC, Martin M, et al. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2021;22(2):212–22.

[36] Segovia-Mendoza M, Morales-Montor J. Immune tumor microenvironment in breast cancer and the participation of estrogen and its receptors in cancer physiopathology. Front Immunol 2019;10:348.

[37] U.S. Food and Drug Administration. FDA approves pembrolizumab for high-risk early-stage triple-negative breast cancer 2021. https://www.fda.gov/drugs/press-announcements/fda-approves-pembrolizumab-high-risk-early-stage-triple-negative-breast-cancer. [Accessed 31 January 2020].

[38] Caviglia G, Lenihan D, Bradley M, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol 2020;31(2):171–90.

[39] Armenian SH, Lacerini C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American society of clinical oncology clinical practice guideline. J Clin Oncol 2017;35(8):893–911.

[40] von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med 2017;377(2):122–31.

[41] Hudson CA, Barlow WE, Costantino JP, et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 2007;25(15):2127–32.

[42] Tolaney SM, Garrett-Mayer E, White J, et al. Updated standardized definitions for efficacy end points (STEEP) in adjuvant breast cancer clinical trials: STEEP version 2.0. J Clin Oncol 2021;39(24):2720–31.

[43] Anderson RA, Ciatto F, Demeestere I, et al. Cancer survivorship: reproductive health outcomes should be included in standard toxicity assessments. Eur J Cancer 2021;144:310–6.